Adding a GLP-1/GIP Drug to Ixekizumab May Boost Psoriasis Clearance in People with Obesity, Early Trial Finds
For the millions of people living with plaque psoriasis, achieving clear skin can feel like an uphill battle—especially when excess weight fuels chronic inflammation and dampens treatment response. Now, a clinical trial has tested a bold combination: a next-generation weight-loss drug plus a proven biologic. The results indicate that this duo may offer meaningful gains for patients who have struggled to get their psoriasis under control. While the data are still emerging, the signals are strong enough to reshape how clinicians think about treating inflammatory skin disease in the context of obesity.
Why Weight Matters in Psoriasis
Psoriasis is not just a skin condition. It is a systemic inflammatory disease driven by an overactive immune response, and research has long established a two-way street between psoriasis and obesity. Excess fat tissue releases pro-inflammatory molecules such as tumor necrosis factor (TNF) and interleukin-6, which can worsen skin plaques and make standard therapies less effective. In turn, the discomfort, stigma, and psychological burden of psoriasis can reduce physical activity and promote weight gain.
For years, dermatologists have observed that obese patients often respond less robustly to biologics like ixekizumab, an interleukin-17A inhibitor approved for moderate-to-severe plaque psoriasis. Weight loss—whether through lifestyle changes or bariatric surgery—has been shown to improve treatment outcomes, but sustained weight reduction is notoriously difficult. The arrival of glucagon-like peptide-1 (GLP-1) receptor agonists, and later dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor co-agonists, has opened a new door. These medications not only promote significant weight loss but also appear to possess direct anti-inflammatory properties that might benefit psoriasis independently of weight reduction.
The Evidence: What the TOGETHER-PsO Trial Found
The trial that is generating buzz is called TOGETHER-PsO, an open-label study that evaluated the addition of a dual GLP-1/GIP receptor agonist to ixekizumab treatment. While the complete dataset awaits peer-reviewed publication or presentation at a medical congress, MedPage Today reported that the combination “significantly improved outcomes” in adults with difficult-to-treat plaque psoriasis who were overweight or living with obesity.
Several important details are currently unavailable. The lead author’s name and institutional affiliation were not disclosed in the preliminary report, nor was the journal or medical meeting where the findings will be formally presented. The researchers did not release the sample size, specific percentages of skin clearance (such as PASI 75, PASI 90, or PASI 100 response rates), risk ratios, confidence intervals, or the duration of follow-up. Because the trial was open-label—meaning both patients and investigators knew which treatments were being given—there is a heightened possibility of bias compared to a double-blind, placebo-controlled design. Nonetheless, the signal that the combination outperformed ixekizumab alone in a population with notoriously poor response is noteworthy.
The dual GLP-1/GIP receptor agonist class, which includes tirzepatide (Mounjaro for type 2 diabetes, Zepbound for weight loss), has shown impressive weight reduction and improvements in multiple cardiometabolic markers. Its potential in dermatology is an active area of investigation. Mechanistically, GLP-1 receptors are expressed on immune cells and skin cells, and activation may dampen Th17-mediated inflammation—the very pathway ixekizumab targets. By attacking psoriasis through both weight-related and direct anti-inflammatory mechanisms, the combination could offer a synergistic benefit.
What This Means for You
If you are living with plaque psoriasis and carrying extra weight, these early findings could be a reason for cautious optimism—but not for an immediate change in your treatment. The TOGETHER-PsO trial underscores that addressing metabolic health alongside skin inflammation might yield better results than either strategy alone. However, dual GLP-1/GIP agonists are not currently approved for psoriasis, and using them for this purpose would be off-label. Insurance coverage and long-term safety data in a dermatology context are also missing.
What you can do right now is have an informed conversation with your dermatologist and primary care provider. Ask about the role your weight might play in your psoriasis severity, and whether a referral to an obesity medicine specialist could help. If you are already on ixekizumab and losing weight with lifestyle changes or medication, do not stop or alter your regimen without medical guidance. The combination approach is still investigational, and more solid data are needed before it becomes part of standard care. Keeping an eye on upcoming medical conferences and peer-reviewed journals will be key, as the full TOGETHER-PsO results may provide the clarity that clinicians and patients need.
Expert Perspective and Study Limitations
Because no named researcher or external commentary was included in the preliminary news release, an independent expert perspective is not available. However, clinicians reading these early signals will likely note several limitations. Open-label designs are prone to placebo effect and observer bias. Without a control group receiving only ixekizumab plus a weight-loss placebo, it is impossible to quantify how much of the observed improvement came from the drug’s direct anti-inflammatory effect versus weight loss alone. Additionally, the side-effect profile of combining a biologic with a dual incretin agonist requires careful scrutiny; gastrointestinal disturbances, rare pancreatitis, and the potential for gallbladder issues are known risks of the GLP-1/GIP class. Future randomized, double-blind trials with longer follow-up and a diverse patient population will be necessary to confirm the benefit and establish safety.
Frequently Asked Questions
Q: What exactly is a dual GLP-1/GIP receptor agonist?
A dual GLP-1/GIP receptor agonist is a medication that mimics two natural hormones—GLP-1 and GIP—involved in blood sugar regulation and appetite control. By activating both receptors, these drugs enhance insulin secretion, slow stomach emptying, and reduce appetite, leading to substantial weight loss. Tirzepatide is the first approved drug in this class.
Q: How does weight loss improve plaque psoriasis?
Excess fat tissue releases pro-inflammatory cytokines that fuel the systemic inflammation underlying psoriasis. Weight loss reduces this inflammatory burden, which can make the skin less reactive to immune triggers and enhance the effectiveness of treatments like ixekizumab. Even modest weight reductions of 5-10% have been linked to better treatment response in some studies.
Q: Is this combination therapy available to patients now?
Not as a standard psoriasis treatment. The TOGETHER-PsO trial is investigational, and dual GLP-1/GIP agonists do not carry an FDA indication for plaque psoriasis. However, some patients with obesity and psoriasis may receive these drugs off-label or as part of a clinical trial. Always consult your healthcare provider before considering any new combination therapy.
Q: What other GLP-1 drugs have been studied for skin conditions?
Semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda, Victoza) have shown promise in smaller studies and case reports for improving psoriasis, hidradenitis suppurativa, and other inflammatory skin diseases. Most evidence remains preliminary, with larger controlled trials underway. The dual agonist class is a newer frontier that may offer additional weight loss and anti-inflammatory potency.
Q: Are there any special risks when combining a biologic with a GLP-1/GIP drug?
The safety profile of this specific combination has not been fully established. General concerns include overlapping gastrointestinal side effects, potential injection-site reactions, and rare events like pancreatitis. Because both drugs modulate the immune system, the long-term risk of infection or malignancy needs evaluation in larger studies. Patients in the TOGETHER-PsO trial will need to be monitored for any unexpected adverse events.
Sources
- MedPage Today (2025). GLP-1 Drug Makes Its Case for Treating Plaque Psoriasis. MedPage Today. Available at medpagetoday.com.
